Premium
LecT‐hepa, a glyco‐marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients
Author(s) -
Ito Kiyoaki,
Kuno Atsushi,
Ikehara Yuzuru,
Sugiyama Masaya,
Saito Hiroaki,
Aoki Yoshihiko,
Matsui Teppei,
Imamura Masatoshi,
Korenaga Masaaki,
Murata Kazumoto,
Masaki Naohiko,
Tanaka Yasuhito,
Hige Shuhei,
Izumi Namiki,
Kurosaki Masayuki,
Nishiguchi Shuhei,
Sakamoto Michiie,
Kage Masayoshi,
Narimatsu Hisashi,
Mizokami Masashi
Publication year - 2012
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.25815
Subject(s) - cirrhosis , fibrosis , gastroenterology , medicine , hepa , pathology , filter (signal processing) , computer science , computer vision
Assessment of liver fibrosis in patients with chronic hepatitis C (CHC) is critical for predicting disease progression and determining future antiviral therapy. LecT‐Hepa, a new glyco‐marker derived from fibrosis‐related glyco‐alteration of serum alpha 1‐acid glycoprotein, was used to differentiate cirrhosis from chronic hepatitis in a single‐center study. Herein, we aimed to validate this new glyco‐marker for estimating liver fibrosis in a multicenter study. Overall, 183 CHC patients were recruited from 5 liver centers. The parameters Aspergillus oryzae lectin (AOL) / Dature stramonium lectin (DSA) and Maackia amurensis lectin (MAL)/DSA were measured using a bedside clinical chemistry analyzer in order to calculate LecT‐Hepa levels. The data were compared with those of seven other noninvasive biochemical markers and tests (hyaluronic acid, tissue inhibitor of metalloproteases‐1, platelet count, aspartate aminotransferase‐to‐platelet ratio index [APRI], Forns index, Fib‐4 index, and Zeng's score) for assessing liver fibrosis using the receiver‐operating characteristic curve. LecT‐Hepa correlated well with the fibrosis stage as determined by liver biopsy. The area under the curve (AUC), sensitivity, and specificity of LecT‐Hepa were 0.802, 59.6%, and 89.9%, respectively, for significant fibrosis; 0.882, 83.3%, and 80.0%, respectively, for severe fibrosis; and 0.929, 84.6%, and 88.5%, respectively, for cirrhosis. AUC scores of LecT‐Hepa at each fibrosis stage were greater than those of the seven aforementioned noninvasive tests and markers. Conclusion : The efficacy of LecT‐Hepa, a glyco‐marker developed using glycoproteomics, for estimating liver fibrosis was demonstrated in a multicenter study. LecT‐Hepa given by a combination of the two glyco‐parameters is a reliable method for determining the fibrosis stage and is a potential substitute for liver biopsy. (H EPATOLOGY 2012)